| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell, Tumor, and Stem Cell Biology |
1 Molecular Urology and Therapeutics Program, Department of Urology and Winship Cancer Institute, 2 Microchemical and Proteomics Facility, and 3 Divison of Endocrinology and Metabolism and Lipids, Emory University School of Medicine, Atlanta, Georgia; 4 Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama; and 5 Department of Biological Science, University of Delaware, Newark, Delaware
Requests for reprints: Leland W.K. Chung, Molecular Urology and Therapeutics Program, Department of Urology and Winship Cancer Institute, Emory University School of Medicine, 1365-B Clifton Road, Room B5101, Atlanta, GA 30322. Phone: 404-778-3672; Fax: 404-778-3675; E-mail: lwchung{at}emory.edu.
The protein factor ß2-microglobulin (ß2M), purified from the conditioned medium of human prostate cancer cell lines, stimulated growth and enhanced osteocalcin (OC) and bone sialoprotein (BSP) gene expression in human prostate cancer cells by activating a cyclic AMP (cAMP)dependent protein kinase A signaling pathway. When ß2M was overexpressed in prostate cancer cells, it induced explosive tumor growth in mouse bone through increased phosphorylated cAMP-responsive element binding protein (CREB) and activated CREB target gene expression, including OC, BSP, cyclin A, cyclin D1, and vascular endothelial growth factor. Interrupting the ß2M downstream signaling pathway by injection of the ß2M small interfering RNA liposome complex produced an effective regression of previously established prostate tumors in mouse bone through increased apoptosis as shown by immunohistochemistry and activation of caspase-9, caspase-3, and cleavage of poly(ADP-ribose) polymerase. These results suggest that ß2M signaling is an attractive new therapeutic target for the treatment of lethal prostate cancer bone metastasis. (Cancer Res 2006; 66(18): 9108-16)
This article has been cited by other articles:
![]() |
W.-C. Huang, J. J. Havel, H. E. Zhau, W. P. Qian, H.-W. Lue, C.-Y. Chu, T. Nomura, and L. W.K. Chung {beta}2-Microglobulin Signaling Blockade Inhibited Androgen Receptor Axis and Caused Apoptosis in Human Prostate Cancer Cells Clin. Cancer Res., September 1, 2008; 14(17): 5341 - 5347. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Chu, C.-J. Cheng, X. Ye, Y.-C. Lee, A. J. Zurita, D.-T. Chen, L.-Y. Yu-Lee, S. Zhang, E. T. Yeh, M. C-T. Hu, et al. Cadherin-11 Promotes the Metastasis of Prostate Cancer Cells to Bone Mol. Cancer Res., August 1, 2008; 6(8): 1259 - 1267. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gross, I. Top, I. Laux, J. Katz, J. Curran, C. Tindell, and D. Agus {beta}-2-Microglobulin Is an Androgen-Regulated Secreted Protein Elevated in Serum of Patients with Advanced Prostate Cancer Clin. Cancer Res., April 1, 2007; 13(7): 1979 - 1986. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Nomura, W.-C. Huang, H. E. Zhau, D. Wu, Z. Xie, H. Mimata, M. Zayzafoon, A. N. Young, F. F. Marshall, M. N. Weitzmann, et al. {beta}2-Microglobulin Promotes the Growth of Human Renal Cell Carcinoma through the Activation of the Protein Kinase A, Cyclic AMP-Responsive Element-Binding Protein, and Vascular Endothelial Growth Factor Axis Clin. Cancer Res., December 15, 2006; 12(24): 7294 - 7305. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |